TY  - JOUR
AU  - Peters, Andreas S
AU  - Wortmann, Markus
AU  - Fleming, Thomas H
AU  - Nawroth, Peter P
AU  - Bruckner, Thomas
AU  - Böckler, Dittmar
AU  - Hakimi, Maani
TI  - Effect of metformin treatment in patients with type 2 diabetes with respect to glyoxalase 1 activity in atherosclerotic lesions.
JO  - Vasa
VL  - 48
IS  - 2
SN  - 1664-2872
CY  - Göttingen [u.a.]
PB  - Huber
M1  - DKFZ-2019-01322
SP  - 186 - 192
PY  - 2019
AB  - The enzyme glyoxalase1 (GLO1) is the main opponent in the degradation of the reactive metabolite methylglyoxal (MG), which by glycation of macromolecules is involved in atherogenesis. Reduced GLO1-activity in atherosclerotic tissue is known to be associated with diabetes. It has been shown that treatment of patients with type 2 diabetes with metformin leads to increased GLO1-activity in peripheral-blood-cells. The aim of this study was to evaluate whether metformin treatment increases GLO1-activity in atherosclerotic lesions of patients with type 2 diabetes.Patients with type 2 diabetes and carotid artery disease were included into the study prospectively. Type of diabetes-medication was documented upon admission along with demographic and clinical history. Using shock frozen endarterectomy-derived carotid artery plaques, GLO1-activity as well as protein expression was measured by a spectophotometric assay and western-blotting respectively.33 patients (76 
KW  - Metformin (NLM Chemicals)
KW  - Lactoylglutathione Lyase (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:30421661
DO  - DOI:10.1024/0301-1526/a000762
UR  - https://inrepo02.dkfz.de/record/143753
ER  -